Apr 18
Proxy statement
DEF 14A
Meeting Jun 1, 2022
Proxy statement
KROS · Keros Therapeutics, Inc. · Documents
$10.08
+0.54 (+5.66%)
At close · Nov 12
Return incl. dividend (before tax)
Market Cap
$197.81M
Shares
19.62M
Volume · Nov 12
630.16K
Avg daily vol (3M)
187.94K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2022
Apr 18
Proxy statement
DEFA14A
Proxy statement
Mar 9
Current report
8-K
Financial results
Mar 9
Current report
8-K
Regulation FD disclosure
Mar 9
Annual report
10-K
FY2021, ended Dec 31
Annual report for FY2021
Revenue $20.1M
Net loss $58.74M
Diluted EPS -$2.52
Feb 11
Current report
8-K
Regulation FD disclosure
Jan 31
Current report
8-K
Events of Jan 28
Director or officer change, or executive pay, Other events
2021
Dec 13
Current report
8-K/A
Other events
Dec 13
Current report
8-K
Events of Dec 12
Entered into a material agreement, Other events
Dec 13
Current report
8-K
Other events
Nov 22
Current report
8-K
Regulation FD disclosure
Nov 15
Current report
8-K
Other events
Nov 12
Current report
8-K
Events of Nov 11
Regulation FD disclosure
Nov 4
Current report
8-K
Financial results
Nov 4
Current report
8-K
Regulation FD disclosure
Nov 4
Quarterly report
10-Q
FY2021 Q3, ended Sep 30
Quarterly report for FY2021 Q3
Revenue $0
Net loss $20.3M
Diluted EPS -$0.87
Oct 4
Current report
8-K
Other events
Sep 9
Current report
8-K
Events of Sep 7
Entered into a material agreement, New debt or off-balance-sheet obligation
Sep 2
Current report
8-K
Regulation FD disclosure
Aug 5
Current report
8-K
Events of Aug 4
Entered into a material agreement, Financial results
Aug 5
Quarterly report
10-Q
FY2021 Q2, ended Jun 30
Quarterly report for FY2021 Q2
Revenue $100K
Net loss $15.62M
Diluted EPS -$0.67
Aug 2
Current report
8-K
Events of Jul 30
Director or officer change, or executive pay, Other events
Jun 22
Current report
8-K
Regulation FD disclosure, Other events
Jun 11
Current report
8-K
Other events
Jun 1
Current report
8-K
Shareholder vote results
May 27
Current report
8-K
Regulation FD disclosure
May 25
Current report
8-K
Other events
May 14
Current report
8-K
Other events
May 12
Current report
8-K
Other events
May 6
Current report
8-K
Financial results
May 6
Current report
8-K
Regulation FD disclosure
May 6
May 3
Registration statement
S-3ASR
Registration statement
Apr 19
Proxy statement
DEF 14A
Meeting Jun 1, 2021
Proxy statement
Apr 19
Proxy statement
DEFA14A
Proxy statement
Mar 25
Current report
8-K
Financial results
Mar 25
Current report
8-K
Regulation FD disclosure
Mar 25
Mar 5
Current report
8-K
Other events
Mar 2
Current report
8-K
Regulation FD disclosure
Feb 17
Current report
8-K
Regulation FD disclosure
2020
Dec 21
Current report
8-K
Regulation FD disclosure
Dec 17
Current report
8-K
Events of Dec 14
Director or officer change, or executive pay
Dec 7
Current report
8-K
Other events
Nov 17
Current report
8-K
Other events
Nov 13
Current report
8-K
Events of Nov 12
Other events
Nov 10
Current report
8-K
Financial results, Regulation FD disclosure
Nov 10
Current report
8-K
Other events
Nov 10
Quarterly report
10-Q
FY2020 Q3, ended Sep 30
Quarterly report for FY2020 Q3
Revenue $0
Net loss $12.04M
Nov 10
Registration statement
S-1
Registration statement
Showing 151–200 of 216 documents
Key facts
CIK
1664710
CUSIP
492327101
13F (30d)
85 filings
70 filers
Visit website
Investor relations